Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126704) titled 'A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: 1ST Biotherapeutics, Inc.
Condition:
Healthy
Intervention:
Drug: FB-101
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 2025
Target Sample Size: 72
Countries of Recruitment:
Korea, Republic of
To know more, visit htt...